DMD #17707
6 using CO 2 supercritical extraction was obtained from Masson Pharmaceutical Ltd.
(Guangzhou, China). Senkyunolide I (99% pure) and senkyunolide H (94% pure) were isolated from Chuanxiong extract in our laboratory (Li et al., 2003) . Concentration of the only commercially available ligustilide was too low for in vivo studies. This preparation was, therefore, utilized in the in vitro metabolic and stability studies only. For the in vivo studies, ligustilide was isolated from Chuanxiong extract in our laboratory using a previously developed method (Li et al., 2003) . Due to the instability of ligustilide in its pure form as reported previously (Cui et al., 2006; Lin et al., 1998) , the chromatographically 'purified' ligustilide also contained 5% of butylidenephthalide.
Identities of all isolated compounds were confirmed by matching their retention times, UV and MS spectra with those of the authentic standards using our previously developed HPLC-UV-MS method (Li et al., 2003) and their purities were determined using the HPLC-UV method developed by our group (Yan et al., 2005) . Furthermore, contents of ligustilide, butylidenephthalide, and other phthalides in Chuanxiong extract (Table 1) were also determined using the same manner. The ratio of ligustilide and butylidenephthalide in Chuanxiong extract was found to be 18:1, similar to that found in the 'purified' ligustilide.
In vivo Protocols Male Sprague-Dawley (SD) rats (200-230 g) were supplied by the Laboratory Animal Service Center, The Chinese University of Hong Kong. Animals were housed under standard conditions of temperature, humidity and light. Food and water were provided ad libitum. A well-established in vivo pharmacokinetic model in the rat (Su et al., DMD #17707 7 receiving intravenous dosing, a femoral vein cannula was also implanted. After cannulation, rats were allowed to recover and fasted overnight with free access to water.
For intravenous (iv) administration, the 'purified' ligustilide sample (ligustilide dose: 15.6 mg/kg) or Chuanxiong extract (100 mg/kg, ligustilide dose: 14.9 mg/kg) formulated in Pharmatek formulation-6 (Pharmatek, San Diego, CA, USA) was injected into the left femoral vein through the catheter. A single dose of ligustilide formulated in normal saline containing 3% Tween-80 was given orally (100, 360 or 500 mg/kg) or intraperitoneally (ip) (26 or 52 mg/kg) to individual groups of rats. Blood (~0.3 mL/sample) was collected into heparinized Eppendorf tubes at appropriate time intervals over a 48-hr period as illustrated in Fig. 2 . After each collection, 0.3 mL of saline containing 40 IU heparin/mL was injected to compensate for blood loss. Blood samples were centrifuged at 3000 × g for 10 min and plasma samples were harvested. Each plasma sample (160 µL) was mixed with 5 µL of internal standard (α-naphthaflavone, 40 µg/mL) and 165 µL of acetonitrile, vortexed and centrifuged at 16000 × g for 5 min. The supernatant was filtered with a 0.45 µm syringe filter, and 100 µL of the filtrate was subjected to HPLC analysis.
In vitro Metabolic Study Pooled (5 untreated male SD rats) liver and small intestine homogenates (S9) and microsomes were prepared using standard methods (Lin et al., 2000; 2007; Williams et al., 1989) . Total contents of protein and cytochrome P450 were measured using the Lowry (Lowry et al., 1951) and the Omura method (Omura and Sato, 1964) , respectively. The reaction components contained one of the subcellular preparations (2 mg protein/mL) described above, ligustilide (5 to 800 µM), NADPH-regenerating system (1 mM NADP + , 1 mM NAD + , 10 mM glucose-6-phosphate, 2 units/ml glucose-6-phosphate dehydrogenase, 4 mM MgCl 2 ), 50 mM Tris buffer containing 150 mM of KCl DMD #17707 8 (pH 7.4) in a total volume of 1 mL. There were three types of control samples: one contained no NADPH-regenerating system; one had neither substrate nor NADPHregenerating system and one had the protein of the subcellular fraction denatured by heat.
Reactions were initiated by the addition of NADPH-regenerating system, or substrate in case of the control containing no NADPH-regenerating system. The mixture was incubated for 1 hr at 37 °C with gentle shaking. The reaction was terminated by the addition of an equal volume of acetonitrile containing the internal standard; the mixture was kept on ice for 5 min. The resultant sample was centrifuged, filtered, and 100 µL of filtrate was subjected to HPLC analysis. All controls and reactions were processed in parallel. Each sample was processed in triplicate. The mixtures were incubated for 1 hr at 37 °C. Aliquots (100 µL) of incubates were collected at 0, 5, 15, 30 and 60 min. Each aliquot was immediately extracted with ethyl acetate (200 µL), followed by centrifugation at 500 × g for 5 min. After removing the organic layer, the sample was extracted again with the same procedure. The organic layers were combined and an aliquot (150 µL) was mixed with 150 µL of methanol containing 1.75 µg of α-naphthaflavone. The resultant solution was filtered and an aliquot (100 µL) of the filtrate was subjected to HPLC analysis. Each test was conducted in triplicate. Method validation Three concentrations of ligustilide at high, medium and low levels of the corresponding calibration curves were chosen to determine the intra-and inter-day variability. Samples at each concentration were analyzed in triplicates to examine intra-day variability. The inter-day variability was determined on three separate days over a period of one week. Peak area ratio for each concentration was measured, and concentration of ligustilide was calculated from the corresponding calibration curve. Relative standard deviation (RSD) and percentage difference between amounts spiked and determined (recovery) were taken as measures of precision and accuracy, respectively.
Stability of Ligustilide in Simulated Gastric and Intestinal Fluids
Aliquots of methanol stock solution were also spiked into blank plasma or incubation buffer to determine limits of quantification (LOQ) of ligustilide. The resultant samples were treated and analyzed using the procedures described in this section. LOQ was determined when the concentration of a sample has a signal-to-noise ratio at or higher than
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Statistical Analysis All data were expressed as means ± standard deviation (S.D.).
Unpaired student's t-test was used to compare results between two groups of animals receiving ligustilide intraperitoneally, while one-way analysis of variance (ANOVA) followed by Bonferroni's post-hoc test was performed in order to compare results among different groups. Level of p < 0.05 was considered significant.
Results

Validation of the HPLC Method
The HPLC method was demonstrated to be suitable for the quantification of ligustilide in samples collected from the in vitro and in vivo studies. Ligustilide was well separated from its metabolites (Fig. 1 ). The calibration curves for both plasma and incubated samples showed good linearity (r 2 > 0.999 and r 2 > 0.996, respectively) over the concentration ranges tested. The overall intra-and inter-day variations were less than 5% (0.9%─4.2%) and recovery was higher than 87%
(87.9%─99.7%), suggesting good reproducibility and precision. LOQ values for ligustilide were 20 ng/mL and 200 ng/mL in rat plasma and in Tris buffer, respectively. Figure 2 shows plasma concentration-time curves of ligustilide after three routes of administration. The calculated pharmacokinetic parameters are summarized in Table 2 . After intravenous administration, ligustilide exhibited extensive distribution in the body (V d : 3.76±1.23 L/kg) and rapid elimination (t 1/2 : 0.31±0.12 hr) from plasma. The plasma concentration decreased below LOQ after 1.5 hr ( Fig. 2A) . When a low dose of ligustilide (26 mg/kg) was given intraperitoneally (Fig. 2B) , it was rapidly absorbed (T max : 0.05±0.02 hr) and quickly eliminated (t 1/2 : 0.36±0.05 hr).
Pharmacokinetics of Ligustilide
The intraperitoneal bioavailability was estimated to be 52%, indicating an extensive This article has not been copyedited and formatted. The final version may differ from this version. In the case of oral administration of ligustilide, plasma concentration-time profile and pharmacokinetic parameters could only be obtained at the highest dose (500 mg/kg). At lower doses, data were not meaningful because plasma levels of ligustilide were either below detectable limit (at 100 mg/kg) or they were not high enough for accurate pharmacokinetic analysis. At the dose of 500 mg/kg ( Table 2) . Values of CL/F were significantly higher and dose-normalized AUC lower than those obtained after iv and ip dosing. Oral bioavailability was estimated to be 2.6% at 500 mg/kg dose.
The elimination of ligustilide when administered in the form of Chuanxiong extract intravenously was significantly faster than that for its pure form (CL: 20.35±3.05 vs 9.14±1.27 L/hr/kg, p<0.01, Fig. 2A , Table 2 ), suggesting interaction between ligustilide and components present in the extract.
Identification of Metabolites of Ligustilide
Fifteen peaks (L1-L15) were found as potential metabolites in vivo (Fig. 1A-C hydroxyl groups were added in the structures of these two metabolites. Furthermore, their retention time, UV and mass spectra were consistent with those of authentic senkyunolide I and senkyunolide H. These metabolites were generated from hydroxylation of ligustilide (Fig. 4) . The mass spectrum of L13 showed the protonated molecular ion ([M+H] + ) and a sodium adduct ion ([M+Na] + ) at m/z 189 and 211, respectively (Fig. 3) . Its retention time, UV and mass spectra were identical to those of butylidenephthalide, which was formed via aromatization of ligustilide (Fig. 4) . As indicated in Table 1 , L1, L2 and L13 are present in Chuanxiong herb in relatively low quantities (Li et al, 2003; 2007; Yan et al, 2005 to that of 3-hydroxybutylphthalide, a recently identified metabolite of butylidenephthalide in our laboratory (unpublished data). Therefore, L7 was identified as 3-hydroxybutylphthalide, it could be possibly generated from either direct hydration of ligustilide followed by aromatization or hydration of L13 as indicated in Fig. 4 . The detailed information on the structure elucidation of 3-hydroxybutylphthalide will be published in a separate article on the metabolism of butylidenephthalide.
Structures of other three metabolites (L4-L6) were tentatively assigned. Mass spectrum of L4 (Fig. 3) to that of ligustilide, suggesting the presence of an unchanged chromophore of the parent compound. Therefore, oxidation might occur at the end of 3-substituted side chain of ligustilide, and L4 was tentatively identified as 11-hydroxyligustilide. This metabolite was expected to be generated from direct oxidation of ligustilide (Fig. 4) (Fig. 4) . However, the substituted positions for both GSH and hydroxyl group were unable to be unequivocally assigned. Based on the identified seven metabolites, the metabolic pathways of ligustilide in both in vivo and in vitro studies were proposed as shown in Fig. 4 .
In vitro Metabolic Profiles
Ligustilide was neither metabolized in the rat intestinal S9 fractions nor microsomes. When pure ligustilide (300 µM) was incubated with rat hepatic S9 preparations, approximately 60% ligustilide was metabolized in the presence of NADPH-regenerating system (Fig. 1D ), but no significant metabolism was observed in the absence of NADPH-regenerating system (Fig. 1E) . A similar metabolic pattern was found when ligustilide was incubated with hepatic microsomes. After ligustilide was incubated with hepatic microsomes in the presence of NADPH-regenerating system for 1 hr, over 98% of the substrate was metabolized. The most abundant metabolite generated was L1 (~ 21% of ligustilide), while L13 was identified as a minor metabolite (0.88% of ligustilide).
The metabolic rate was rapid, significant saturation was not attained at concentration as high as 800 µM (Fig. 5 ). However, due to solubility constraint, accurate Michaelis-Menton parameters, such as V max and K m , for ligustilide could not be determined. The results indicated that ligustilide mainly underwent NADPH-dependent metabolism in the rat liver, which might be responsible for its extensive hepatic first-pass effect observed in vivo. Chuanxiong is one of the most commonly prescribed CM herbs for the treatment of cardiovascular diseases in China. However, pharmacokinetics of the main bioactive ingredients in this herb is largely unknown. There is only one published study on the oral pharmacokinetics of ligustilide (Shi et al., 2006) . However, it is difficult to compare the reported results directly with our current findings, because the published protocol and sample preparations were not described accurately in detail. Moreover, oral bioavailability was not determined (Shi et al., 2006) . In the present study, pharmacokinetics of ligustilide was investigated. The isolated ligustilide sample, which contained 5% butylidenephthalide with the composition ratio of two phthalides similar to that in the extract (approximately 18:1, Table 1 ), was utilized because 1) concentration of commercially available ligustilide was too low for in vivo dosing; and 2) pure ligustilide is light and thermally labile, but stable when kept in solvents, media, or mixed with other compounds (Cui et al., 2006; Li et al., 2007) .
Stability of Ligustilide in Simulated Gastric and Intestinal Fluids
This article has not been copyedited and formatted. The final version may differ from this version. The results demonstrated that ligustilide was rapidly absorbed after ip and oral dosing and exhibited extensive distribution and rapid elimination after iv administration. The terminal phase after oral administration was significantly longer (p<0.001) than that of other two routes (Fig. 2) . Given the oral bioavailability is less than 3%, the concentration achieved at the portal system during absorption was unlikely to be high enough to saturate hepatic enzymes; therefore nonlinear metabolism which leads to slower elimination is unlikely. However, the mechanism behind this observation is not clear. In vitro metabolic studies ( concentration as high as 800 µM in vitro. Furthermore, the elimination profiles after low and high ip dose were not significantly different from each other (Fig. 2B) . The total body clearance value was much higher than that of hepatic blood flow, suggesting extrahepatic elimination is involved. However, it is not certain as to how extrahepatic elimination is involved. The disproportionate increase in AUC after a high dose of ligustilide may be due to saturation of non-specific binding in the liver. More study is required to elucidate this hypothesis.
In this study, constituents in Chuanxiong extract were found to significantly increase clearance of ligustilide (CL: 20.35±3.05 vs 9.14±1.27 L/hr/kg, p<0.01). The elimination of ligustilide is so high that it is likely to be flow limited. Since Chuanxiong and its products are used for the relief of pain induced by blood stagnation (China Pharmacopoeia, 2005) , it is possible that the increase in ligustilide clearance may be a direct result of hepatic blood flow change. However, to date there is no published evidence supporting this contention.
Interestingly, no significant pharmacokinetic interactions between senkyunolide A and components in Chuanxiong were found previously (Yan et al., 2007) . Mechanisms responsible for pharmacokinetic interaction of ligustilide are unknown and worthy of investigation. The results revealed a variable and unpredictable pharmacokinetics of ligustilide, depending on components concurrently administered. Nevertheless, it is common to take more than one ingredient in herbal therapy. Therefore, therapeutic outcomes may vary when different Chuanxiong-based herbal preparations are utilized.
Eight ligustilide metabolites were identified both in vivo and in vitro.
Butylidenephthalide, senkyunokide I, senkyunolide H and 3-hydroxybutylphthalide were unequivocally characterized; 11-hydroxyligustilide and two isomers of hydroxyligustilide This article has not been copyedited and formatted. The final version may differ from this version. glutathione conjugate were tentatively identified, while structure of L8 was not elucidated.
Several other peaks, which were only observed in chromatograms of plasmas after dosing but not in the incubated samples and blank plasma (Fig. 1) , showed no ligustilide-related ions in their mass spectra and thus were not identified. The proposed metabolic pathways of ligustilide were reported for the first time (Fig. 4) . All metabolites were formed via oxidation pathways mediated by NADPH-dependent monooxygenases, and two were subsequently converted to glutathione conjugates. Butylidenephthalide, senkyunokide I
and senkyunolide H also occur naturally in Chuanxiong (Li et al., 2003; Yan et al., 2005) , and have been reported to produce various pharmacological activities (Chan et al., 2006; Liang et al., 2005; Kobayashi et al., 1992) . Being naturally present in herb and also as metabolites in vivo, it obviously make overall effects of all bioactive ingredients and their individual contributions in the body more complicated and difficult to be predicted.
Therefore, it should be emphasized that quality control of the bioactive ingredients in
Chuanxiong and its products must consider not only herbal contents but also quantities of their active metabolites in vivo. 
